In a multicentre randomized trial of the EORTC-ECSG, we have treated 38 chemotherapy naive patients with advanced non-small-cell lung cancer (NSCLC) with EO9, a novel bioreductive alkylating indoloquinone. The drug was given at two different dose schedules by a single bolus i.v. injection: arm A 12 mg/m 2 weekly and arm B 22 mg/m 2 every three weeks. All together 185 courses were administered (145 in arm A and 40 in arm B). The major toxicity was reversible proteinuria more frequently occurring in the three-weekly schedule (arm A 34.5% vs. arm B 62.5%). Creatinine elevation, fluid retention and pericardial or pleural effusion were also recorded in a limited number of patients. Other common toxicities more frequent in the three-weekly administration were asthenia (21% vs. 35% of cycles), nausea (15% vs. 27.5% of cycles) and vomiting (5% vs. 17.5% of cycles). Toxicities were mainly of grade I and n. No responses have been observed. Five patients (26%) on arm A and eight (53%) on arm B experienced stable disease. These doses and schedules of EO9 do not yield activity in NSCLC.
Introduction
EO9 [3-hydroxy-5-aziridinyl-l-methyl-2 (lH-indole-4, 7-indione)-propenol] is the lead compound in a series of novel bioreductive alkylating indoloquinones. It is fully synthetic and structurally related to mitomycin. Recently, it has been demonstrated that EO9 is able to function in vitro as a substrate for human and murine DT-diaphorase [1, 2] . EO9 has been selected for clinical trials because of its activity in human tumor cell lines and in murine tumor models both in vitro and in vivo [3] [4] [5] .
Phase I trials with EO9 were performed with threeweekly and one-weekly schedules [6] . The dose limiting toxicity in both schedules was transient and reversible proteinuria and renal toxicity. Other side effects were nausea and vomiting, asthenia, malaise and fatigue. Hematologic toxicity was minimal.
We have conducted a phase II randomized trial of EO9 with two different treatment schedules in order: (a) to assess their feasibility, (b) to evaluate the therapeutic effectiveness of the drug, and (c) to further characterize the toxicity between the two groups.
Patients and methods
Eligibility criteria included histologically or cytologically proven and measurable advanced disease, WHO performance status <2, age 18-75 years; and adequate bone marrow, hepatic and renal function. Among the usual exclusion criteria the presence of proteinuria, of prior chemotherapy and of previous radiotherapy to a lesion used to assess response were included.
Following randomization treatment was given as a 5-minute single bolus i.v. injection either at a dose of 12 mg/m 2 once every week (arm A) or at a dose of 22 mg/m 2 every three weeks (arm B). The drug was diluted in sterile 0.9% saline to a final concentration of 0.5 mg/ml. For both treatment arms, retreatment was delayed for one week in case of: (a) proteinuria grade 2 (++ to +++ or 0.3-1.0 g% or 3-10 g/1), (b) increase of serum creatinine >grade 1 (> 1.5 x the upper limit of normal), (c) hematologic toxicity >grade 3, or (d) other toxicity of > grade 2 at day of retreatment except alopecia. No dose reduction was allowed. If the treatment had to be delayed for more than two weeks, the patient was withdrawn from the study. Responses were assessed according to the standard WHO criteria. First response evaluation was performed six weeks after entry into the study. When progression was observed between three and six weeks after entry into the study, this was classified as 'early progression'. Progression could not be defined prior to three weeks (one full cycle) after entry into the study, patients removed from the study at earlier times for whatever reason were considered non-evaluable for response. Toxicity was defined by CTC Criteria.
Results
Thirty-nine patients were entered into the trial and 38 were eligible (Table 1) . One patient in arm B was considered as non-eligible due to the lack of measurable lesions.
In total 145 courses were administered (1-12 cycles per patient) in arm A and 40 (1-6 cycles per patient) in arm B. All courses in arm A were given at 12 mg/m 2 , while in arm B 39 courses (97.5%) at 22 mg/m 2 and one course at 18 mg/m 2 due to non-drug related reason. Treatment delays were recorded in 16 (11%) cycles of arm A and in five (12.5%) of arm B. In arm A, eight cycle delays were due to non-hematologic toxicity, six to non-drug related reasons and two to drug supply. In arm B, three cycle delays were attributed to nonhematologic toxicity and two to non-drug related reasons. Changes in treatment duration were recorded in six courses in arm B.
In one of these patients serum creatinine elevation of grade I was also found, while in two others edema of grade I and II was noticed. In arm A proteinuria was observed in 35% of courses mainly of grade I. In arm B proteinuria was recorded in 62.5% of administrations mainly of grade I and H In one of these patients edema and pleural effusion, in another edema and pericardial effusion and in a third one edema, elevated serum creatinine and both pericardial and pleural effusions were also observed (Table 2) . Other non-hematological toxicity consisted of asthenia (21% in arm A, 35% in arm B), nausea (15% in arm A, 27.5% in arm B), vomiting (5% in arm A, 17.5% in arm B), local phlebitis (9% arm A, 12.5% arm B), myalgia (7% arm A, 10% arm B), alopecia (7% arm A, 10% arm B) and headache (3.5% arm A, 5% arm B). Hematological toxicity was minimal consisting of anemia (8% in arm A, 20% in arm B) mainly of grade I. Most of these were pre-existing. No leukopenia, neutropenia or thrombocytopenia of any grade were noticed.
No objective responses were seen. Stable disease was found in five patients (26%) from arm A and in eight (53%) from arm B.
Discussion
From preclinical studies EO9 found to have antitumor activity, whereas from previous phase I trials partial responses were observed in two patients with carcinoma of unknown primary [6] . However, from the present study as well as from other phase II studies conducted by ECSG in breast, colorectal, gastric and pancreatic cancer no activity was noticed [7] . This inactivity might be due to a lack of DT diaphorase positive tumors [8] .
Phase I studies revealed reversible proteinuria and nephrotoxicity as dose limiting. In our arm A proteinuria occurred in 35% of the courses and eight patients had treatment delays due to non-hematological toxicity, however, none of them went off study because of nephrotoxicity. On the contrary, in arm B proteinuria was observed in 62.5% of the courses, while three patients went off study because of excessive toxicity due Table 2 . Drug-related nephrotoxicity per cycle (total n -185). to pericardial effusion, persistent proteinuria and/or renal insufficiency.
From this study it is obvious that the therapeutic window is small, since the 12 mg/m 2 /weekly schedule fails to produce clinical responses, while the 22 mg/ mVthree-weekly dose gives more severe toxicity. Even though there is not much toxicity in the weekly schedule, a higher dose does not seem feasible.
